Pharmaceuticals News

The pharmaceuticals news email from Wiser has been specifically designed for anyone with an interest in the industry. This includes medical practitioners, investors and those involved in research and development. By its very nature, the pharmaceutical industry is subject to constant change. It is a research-driven industry with companies spending much of their revenues developing new medicines and vaccines. As a result patients are able to get new and more effective treatments. This is helping to increase the life expectancy of individuals in most countries. But there are challenges. The costs of the research and development can be large which puts up the price of drugs, while governments and the medical industry argue to try to keep prices as low as possible. The industry also faces challenges from alternatives, both legal (through generic drugs) and illegal (through black market economies). To follow the latest developments in this industry you should sign up for the pharmaceuticals news email from Wiser. It is the best way to find must-read articles on the topic from around the web.

Recent Pharmaceuticals News Coverage
 
Your Weekly Recommendations Saturday, September 23, 2017
 
Recommended for you
Second Opinion | Are you jealous, or simply envious?
CBC Radio-Canada • Kelly Crowe
Zydus Cadila gets USFDA nod to sell hypertension drug
Business Standard • Press Trust
Zydus Cadila gets USFDA nod to sell BP lowering drug
The Hindu Business Line • Pti
Nonadherence to statins plus ACEIs/ARBs risky post MI
Medical Xpress
Effect of osteoporotic fractures similar to diabetes burden
Medical Xpress
Switzerland Struggles To Maintain Key Vaccine Stocks
Eurasia Review • Swissinfo
Ex-Akebia employee suspected of insider trading re-arrested
Reuters • Nate Raymond
Yes on Issue 2 Petitioner Denounces Big Drug Company Ad as Racist and Anti-Semitic
BusinessWire
FDA declines to approve J&J arthritis drug sirukumab
Reuters
US FDA declines to approve J&J arthritis drug
Channel NewsAsia World News
 
Recommended for You
Food & Beverage Industry, Pharmaceuticals
Second Opinion | Are you jealous, or simply envious?
CBC Radio-CanadaKelly Crowe
Hello and happy Saturday! Here's this week's round-up of eclectic and under-the-radar health and medical science news. If you haven't subscribed yet, you can do that by clicking here. Are you jealous,or simply envious? Is a serial killer the same as a...
Share
Pharmaceuticals
Zydus Cadila gets USFDA nod to sell hypertension drug
Business StandardPress Trust
Cadila Healthcare today said its group firm Zydus Cadila has received the final approval from the US health regulator to market blood pressure medicine, Amlodipine and Olmesartan Medoxomil tablets. The nod by US Food and Drug Administration (USFDA) is for multiple strengths...
Share
Pharmaceuticals
Zydus Cadila gets USFDA nod to sell BP lowering drug
The Hindu Business LinePti
The nod is for multiple strengths of the tablets 5mg/40mg; 10mg/20mmg and 10mg/40 mg New Delhi, Sep 23: Cadila Healthcare today said its group firm Zydus Cadila has received the final approval from the US health regulator to market blood pressure medicine,...
Share
Health Care Industry, Hospitals
Nonadherence to statins plus ACEIs/ARBs risky post MI
Medical Xpress
(HealthDay)—Nonadherence to angiotensin-converting enzyme (ACE) inhibitors/angiotensin II receptor blockers (ARBs) and/or statins following acute myocardial infarction (AMI) is associated with higher mortality, according to study published in the Sept. 26 issue of the Journal of the American College of Cardiology. Maarit J....
Share
Pharmaceuticals
Effect of osteoporotic fractures similar to diabetes burden
Medical Xpress
Journal of Evaluation in Clinical Practice. Zoltán Vokó, D.Sc., from Eötvös Loránd University in Budapest, Hungary, and colleagues analyzed data from 840 patients with osteoporosis and 943 patients with diabetes to estimate the effect of osteoporotic fractures and microvascular and macrovascular complications...
Share
Biotechnology, Health Insurance
Switzerland Struggles To Maintain Key Vaccine Stocks
Eurasia ReviewSwissinfo
By Celia Luterbacher It’s one of the wealthiest nations in the world, yet Switzerland is struggling to maintain stocks of 16 key vaccines, forcing doctors to adapt their practices. What’s causing the shortfall, and what’s being done about it? Primarily affected are...
Share
Pharmaceuticals
Ex-Akebia employee suspected of insider trading re-arrested
ReutersNate Raymond
BOSTON () - A former Akebia Therapeutics Inc (AKBA.O) employee accused of insider trading was re-arrested on Friday after violating a bail condition as a prosecutor who once called him “increasingly unhinged” said he would seek the man’s detention pending trial. Schultz...
Share
Pharmaceuticals
Yes on Issue 2 Petitioner Denounces Big Drug Company Ad as Racist and Anti-Semitic
BusinessWire
COLUMBUS, Ohio--(BUSINESS WIRE)--Tracy Jones, one of the original Yes on Issue 2 petitioners, called on the big drug companies and their campaign manager Curt Steiner to pull down their racist and anti-Semitic TV ads off the airwaves. Contemptible racial & anti-semitic stereotyping...
Share
GlaxoSmithKline plc, Health Care Industry
FDA declines to approve J&J arthritis drug sirukumab
Reuters
(Reuters) - The U.S. Food and Drug Administration has declined to approve Johnson & Johnson's rheumatoid arthritis drug sirukumab, saying additional clinical data is needed to further evaluate its safety, the company said on Friday.
Share
Health Care Industry, Pfizer, Inc.
US FDA declines to approve J&J arthritis drug
Channel NewsAsia World News
REUTERS: The U.S. Food and Drug Administration has declined to approve Johnson & Johnson's rheumatoid arthritis drug sirukumab, saying additional clinical data is needed to further evaluate its safety, the company said on Friday. The FDA's decision is in keeping with an...
Share